Αποτελέσματα Αναζήτησης
1 Απρ 2022 · The purpose of the “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” (2022 HF guideline) is to provide an update and to consolidate the “2013 ACCF/AHA Guideline for the Management of Heart Failure” 1 for adults and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure ...
- 2022 Aha/Acc/Hfsa Guideline for The
The webpage provides access to AHA/ASA journals on...
- 2022 Aha/Acc/Hfsa Guideline for The
1 Απρ 2022 · TOP 10 TAKE-HOME MESSAGES. Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) now includes 4 medication classes that include sodium-glucose cotransporter-2 inhibitors (SGLT2i).
1 Απρ 2022 · Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients.
3 Μαΐ 2022 · The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests.
Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients.
14 Φεβ 2020 · SGLT2i (Sodium-glucose co-transporter 2 inhibitors), initially developed for their glucose-lowering potential by blocking renal tubular glucose reabsorption, have been shown to decrease heart failure (HF) events by 27% to 39% in high-risk patients with type 2 diabetes mellitus (T2DM) in 3 cardiovascular outcomes trials 1 and a renal outcomes trial.
27 Μαΐ 2022 · The 2022 guideline stated in patients with heart failure and type 2 diabetes, the use of sodium‑glucose co-transporter‑2 inhibitors is recommended for the management of hyperglycemia and to reduce heart failure-related morbidity and mortality (Class 1, Level A) [1] based on EMPEROR-Reduced [2], DAPA-HF [3], and DECLARE-TIMI 58 [4].
